PIK3CA and cancer: We hypothesise that APOBEC is activated during prior endocrine therapy for advanced cancer, and that this may edit PIK3CA to generate frequent second hit novel mutations12, resulting in hyperactivation of PI3K signalling41 and resistance to fulvestrant endocrine therapy (Fig. 6e).